Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer-Reference-Cited by-同舟云学术

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer

Published:2016-04-16 Issue:5 Volume:77 Page:1097-1102
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Said Rabih,Kakadiaris Eugenia,Piha-Paul Sarina,Fu Siqing,Falchook Gerald,Janku Filip,Wheler Jennifer J.,Zinner Ralph,Hong David S.,Kurzrock Razelle,Tsimberidou Apostolia M.

Funder

Celgene

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3000-3.pdf

Reference25 articles.

1. http://www.fda.gov/downloads/drugs/drugsafety/ucm111335.pdf . 2014

2. Muller GW, Chen R, Huang SY et al (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9:1625–1630

3. Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380–386

4. Sharpe AH, Abbas AK (2006) T-cell costimulation—biology, therapeutic potential, and challenges. N Engl J Med 355:973–975

5. Segler A, Tsimberidou AM (2012) Lenalidomide in solid tumors. Cancer Chemother Pharmacol 69:1393–1406

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy;Trends in Molecular Medicine;2024-08

2. Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report;Surgical Case Reports;2024-02-07

3. Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells;Melanoma Research;2023-07-12

4. How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive;Frontiers in Immunology;2018-02-19

5. CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma;Cancer Research;2017-04-12